The administrative support of UWCCC provides the focal point for achieving "centerness," the integration that is the hallmark of a successful Cancer Center. This nebulous attribute is essential in our institution where depth and breadth of science abound. The challenge is to provide the resources and atmosphere that will induce investigators to look past their traditional departmental silos, focus their expertise on cancer and take advantage of the opportunities for collaborative research that are essential for translation from discovery to application. The leaders of the UWCCC are responsible for creating the resources and collegial opportunities that support this philosophy and the staff of the UWCCC are responsible for creating the atmosphere that attracts investigators and maintains their participation. Therefore UWCCC Administration provides the support necessary for the UWCCC to achieve its mission in the forthcoming five years. The three highest goals of the UWCCC, now and for the future, are: 1) to conduct the highest quality research into the origins and control of cancer;2) to translate these research findings to evaluation in the clinic through well designed clinical trials with corresponding biologic endpoints whenever possible;and 3) to provide the best care possible to all cancer patients by carefully integrating high quality cutting edge care with clinical research in a compassionate and individualized manner. The total budget for the administration of the Cancer Center is $3,188,541. This proposal requests support for 14.8% of the administration operating budget. The rest of the operating budget is supported by institutional support and philanthropic dollars.

Public Health Relevance

UWCCC Administration provides the support necessary for the UWCCC to achieve its mission in the forthcoming five years. The three highest goals of the UWCCC are: 1) to conduct the highest quality research into the origins and control of cancer;2) to translate these research findings to evaluation in the clinic through well designed clinical trials with corresponding biologic endpoints whenever possible;and 3) to provide the best care possible to all cancer patients by carefully integrating high quality cutting edge care with clinical research in a compassionate and individualized manner.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA014520-40
Application #
8762782
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2014-04-01
Budget End
2015-03-31
Support Year
40
Fiscal Year
2014
Total Cost
$336,110
Indirect Cost
$59,442
Name
University of Wisconsin Madison
Department
Type
DUNS #
161202122
City
Madison
State
WI
Country
United States
Zip Code
53715
Oberley, Christopher C; Bilger, Andrea; Drinkwater, Norman R (2015) Genetic background determines if Stat5b suppresses or enhances murine hepatocarcinogenesis. Mol Carcinog 54:959-70
Wisinski, Kari B; Ledesma, Wendy M; Kolesar, Jill et al. (2015) A phase I study to determine the maximum tolerated dose and safety of oral LR-103 (1?,24(S)Dihydroxyvitamin D2) in patients with advanced cancer. J Oncol Pharm Pract 21:416-24
Kolesar, Jill M; Pomplun, Marcia; Havighurst, Tom et al. (2015) Soy food frequency questionnaire does not correlate with baseline isoflavone levels in patients with bladder cancer. J Oncol Pharm Pract 21:128-31
Simoncic, Urban; Perlman, Scott; Liu, Glenn et al. (2015) Comparison of NaF and FDG PET/CT for assessment of treatment response in castration-resistant prostate cancers with osseous metastases. Clin Genitourin Cancer 13:e7-e17
Zhao, Z; Wang, L; Xu, W (2015) IL-13R?2 mediates PNR-induced migration and metastasis in ER?-negative breast cancer. Oncogene 34:1596-607
Chakravarty, Rubel; Hong, Hao; Cai, Weibo (2015) Image-Guided Drug Delivery with Single-Photon Emission Computed Tomography: A Review of Literature. Curr Drug Targets 16:592-609
Wu, Jianqiang; Salva, Katrin A; Wood, Gary S (2015) c-CBL E3 ubiquitin ligase is overexpressed in cutaneous T-cell lymphoma: its inhibition promotes activation-induced cell death. J Invest Dermatol 135:861-8
LoConte, Noelle K; Razak, Albiruni R A; Ivy, Percy et al. (2015) A multicenter phase 1 study of ? -secretase inhibitor RO4929097 in combination with capecitabine in refractory solid tumors. Invest New Drugs 33:169-76
Romens, Sarah E; McDonald, Jennifer; Svaren, John et al. (2015) Associations between early life stress and gene methylation in children. Child Dev 86:303-9
Ayvaci, Mehmet U S; Alagoz, Oguzhan; Chhatwal, Jagpreet et al. (2014) Predicting invasive breast cancer versus DCIS in different age groups. BMC Cancer 14:584

Showing the most recent 10 out of 472 publications